

WAKIX (pitolisant)

Diagnosis Considered for Coverage:

- Treatment of cataplexy associated with narcolepsy
- Treatment of excessive daytime sleepiness (EDS) associated with narcolepsy

Coverage Criteria:

For diagnosis of excessive daytime drowsiness associated with narcolepsy:

- Sleep study confirms narcolepsy, **and**
- Inadequate response or intolerable side effect, or contraindication to modafinil, **and**
- Dose does not exceed FDA label maximum.

For diagnosis of cataplexy associated with narcolepsy:

- Sleep study confirms narcolepsy, **and**
- Dose does not exceed FDA label maximum.

Coverage Duration: one year

Effective Date: 09/27/2023